Related Experiment Video

Updated: May 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Irbesartan in clinical practice]

M V Malishevskiĭ

    Kardiologiia
    |December 15, 2012
    PubMed

    Insights

    Irbesartan effectively treats hypertension and diabetic nephropathy for 24 hours daily. Combined with hydrochlorothiazide, it enhances blood pressure control and offers renoprotective benefits in type 2 diabetes patients.

    Area of Science:

    • Pharmacology
    • Cardiology
    • Nephrology

    Background:

    • Irbesartan is a widely used angiotensin II receptor blocker for hypertension.
    • Long-term use demonstrates its efficacy and safety profile.
    • Its benefits extend beyond blood pressure management.

    Purpose of the Study:

    • To summarize the therapeutic applications and benefits of irbesartan.
    • To highlight its efficacy in managing arterial hypertension and diabetic nephropathy.
    • To underscore its role in cardiovascular and renal protection.

    Main Methods:

    • Review of clinical data and therapeutic outcomes associated with irbesartan use.
    • Analysis of studies investigating irbesartan's effects on blood pressure, cardiac structure, and kidney function.
    • Evaluation of combination therapy with hydrochlorothiazide.

    Main Results:

    • Irbesartan provides 24-hour antihypertensive effect at 150-300 mg/day.
    • Concomitant use with hydrochlorothiazide enhances antihypertensive efficacy.
    • Irbesartan reduces left ventricular hypertrophy and aids in maintaining sinus rhythm post-cardioversion.
    • Demonstrated renoprotective effects in type 2 diabetic patients with varying stages of kidney disease.

    Conclusions:

    • Irbesartan is a safe and effective monotherapy or combination therapy for arterial hypertension.
    • It offers significant benefits for patients with diabetic nephropathy.
    • Its efficacy and patient compliance support its role in contemporary treatment strategies.

    Related Concept Videos

    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...